RxDoctor Payments Data

Margaret Ferris, MD

Clinical Neurophysiology · Stanford, CANPI 1477917565

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $12,475 of the $17,908 with a category attached, or 69.7%. Boston Scientific accounts for 76.9% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $16,217, more than ten times the $51 reported in 2022.

$17,908in general payments, 2019–2025

Across 55 payments — averaging $325.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$14K
  • Bayer$2K
  • Orphalan Inc$2K
  • Medtronic$219
  • Insightec,inc$170
  • AbbVie$43
  • plus $27 from 1 others

What the payments were for

  • Consulting fees$4503%
  • Speaking & faculty fees$12,47570%
  • Travel & lodging$3,04917%
  • Food & beverage$1,93411%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific33$13,776
Bayer11$1,874
Orphalan Inc1$1,800
Medtronic5$219
Insightec,inc2$170
AbbVie2$43
Amgen1$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,908 in reported general payments places this provider in the 85th percentile of 49 clinical neurophysiology providers in California.

See all clinical neurophysiology providers in California

Medicare billing

Part B allowed, 2024
$96,967
Medicare patients
221
Services billed
972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate23$125,249
RytaryCarbidopa/Levodopa64$104,278
MyrbetriqMirabegron13$10,212
Carbidopa-LevodopaCarbidopa/Levodopa204$8,234
Rasagiline Mesylate22$4,070
Entacapone11$3,286
Carbidopa-Levodopa ErCarbidopa/Levodopa70$2,894
AmantadineAmantadine Hcl46$2,847
Rivastigmine11$2,315
Midodrine Hcl27$1,776
Propranolol Hcl ErPropranolol Hcl13$1,489
RivastigmineRivastigmine Tartrate14$939
Primidone39$907
Quetiapine Fumarate33$683
Clonazepam75$503

Paid to pharmacies, not to this prescriber.

Other clinical neurophysiology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →